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Citrate has been recommended as the first-line anticoagulant for continuous renal replacement therapy (CRRT) in
critically ill patients. Compared with heparin, citrate anticoagulation is safer and more efficacious. Citrate inhibits
the coagulation cascade by lowering the ionized calcium (iCa) concentration in the filter. Monitoring of systemic
iCa concentrations is inherent to the protocol, and monitoring of postfilter iCa is recommended to adjust citrate
flow and optimize anticoagulation. While systemic iCa targets are in the physiological range, postfilter iCa
concentrations are targeted between 0.20 and 0.35 mmol/l. In a previous issue of Critical Care, Schwarzer et al.
compared systemic and postfilter iCa measurements of patients receiving citrate-based CRRT between six devices.
They highlight the unreliability of iCa concentrations in the postfilter range, because the instruments cannot be
validated in the low iCa range. The maximum mean difference between two instruments was as high as
0.33 mmol/l (range 0.21–0.50 mmol/l). The authors call for dialysis companies to revise their protocols. However,
the first implication of their study is that the accuracy of blood gas analyzers to measure iCa in the low range
needs to improve; and, secondly, clinicians using citrate anticoagulation need to be aware that the postfilter iCa
result may be falsely high or low. This is particularly relevant when frequent premature filter clotting is observed
despite postfilter iCa results in the seemingly target range. In these situations, citrate flow can be safely increased
up to 4 mmol/l blood flow under monitoring of signs of citrate accumulation.Introduction
Citrate has been recommended as the first-line anti-
coagulant for continuous renal replacement therapy
(CRRT) in critically ill patients. Citrate inhibits the co-
agulation cascade by lowering the ionized calcium (iCa)
concentration through the chelation of calcium in the
filter. A proportion of the calcium citrate complexes is
removed via the filter and the remainder enters the sys-
temic circulation where citrate is rapidly metabolized.
The calcium lost in the effluent has to be replaced.
Monitoring of systemic iCa concentration to guide this
replacement is crucial to the safe application of citrate.
In some protocols, monitoring of postfilter iCa is also
recommended to adjust citrate flow and optimize
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unless otherwise stated.In a recent issue of Critical Care, Schwarzer et al. [1]
highlight a potential problem related to the measure-
ment of postfilter iCa. They measured iCa levels in sys-
temic and postfilter blood from patients undergoing
citrate-based CRRT using six different blood gas
analyzers and found concordance of the systemic iCa
results, but marked discrepancies between postfilter iCa
concentrations. Clinical protocols recommend targeting
postfilter iCa concentrations between 0.20 and 0.35 mmol/
l, because the anticoagulant effect begins when iCa falls
below 0.50 mmol/l and is complete at 0.25 mmol/l [2]. In
the Schwarzer et al. study, the maximum mean difference
between two instruments was 0.33 mmol/l (median
0.29 mmol/l, range 0.21–0.50 mmol/l) for postfilter iCa
values despite internal quality controls within the 14 %
variation of combined imprecision and bias according to
national regulation. It appears that modern blood gas ana-
lyzers are not designed or validated to measure iCa concen-
trations outside the physiologic range. They are
nevertheless used for this purpose in clinical practice.nn. Open Access This article is distributed under the terms of the Creative
e (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
, provided you give appropriate credit to the original author(s) and the source,
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Oudemans-van Straaten and Ostermann Critical Care  (2015) 19:429 Page 2 of 3Importantly, reference methods for measuring low iCa, as
targeted during citrate anticoagulation in the extracorporeal
circuit, are lacking.
Because the reported potential margin of error in the
postfilter iCa results is unacceptably high, the authors
suggest that postfilter iCa monitoring may be question-
able. They also warn about the potential risk of citrate
accumulation as a result of erroneous and misleading
postfilter iCa results and call for a revision of existing
citrate protocols. Although the authors should be con-
gratulated for highlighting a potentially serious problem,
we do not fully agree with all of their conclusions. The
potential danger of citrate toxicity as a result of mislead-
ing iCa results is exaggerated.
Citrate has been recommended as the first-line anti-
coagulant for CRRT in critically ill patients [3]. Com-
pared with heparin, citrate anticoagulation is safer and
confers less bleeding, longer circuit life, and less circuit
downtime [4–7]. The protocols used in these studies are
currently used worldwide, and have shown superiority
over heparin anticoagulation [8], despite using the
potentially inaccurate devices for iCa measurement.
Nevertheless, if postfilter iCa monitoring is part of the
protocol, centers may presently base their decision on
either falsely low, falsely high, or accurate postfilter iCa
concentrations. The question arises as to whether this
poses unnecessary risks for patients. If the results are
falsely low, the citrate dose may be too low for optimal
anticoagulation and this may induce early filter clotting
or reduce the sodium and buffer supply to the patient. If
the iCa results are falsely high, the adjusted citrate dose
may be higher than needed for optimal anticoagulation
in which case more citrate enters the systemic circula-
tion. Is this a problem? Yes, possibly, but only in a small
proportion of patients. It may confer a trend to hyperna-
tremia and alkalosis if citrate metabolism is sufficient, or
may increase the risk of accumulation if metabolism is
limited. However, the overall incidence of accumulation
is low (i.e., around 3 % [9]), with patients with acute liver
failure or decompensated liver cirrhosis being at in-
creased risk. Fortunately, citrate accumulation can easily
be monitored by measuring the total/iCa ratio in the
systemic circulation [10].
The authors call for dialysis companies to revise their
protocols. However, in our opinion, the manufacturers
of blood gas analyzers should be prompted to improve
the accuracy of their devices in the lower than physio-
logical iCa levels. This is particularly important in light
of the rising worldwide trend to use citrate-based
CRRT. It should also be noted that the authors only
tested the accuracy of blood gas analyzers, but not their
precision. Precision relates to reproducibility and de-
scribes the degree to which repeated measurements
show the same result. It remains unclear whether theindividual blood gas analyzers were consistently under-
reading or over-reading.
The two main implications of the study by Schwarzer
et al. are as follows: firstly, the accuracy of blood gas
analyzers to measure iCa in the low range needs to im-
prove; and, secondly, clinicians using citrate anticoagula-
tion need to be aware that the postfilter iCa result may
not be accurate. This is particularly relevant when frequent
premature filter clotting is observed despite postfilter iCa
results in the seemingly target range. It should also be rec-
ognized that monitoring iCa concentrations is not necessar-
ily required because some protocols use a fixed relation
between citrate and blood flow (summarized in [8]). Target-
ing citrate concentration up to 4 mmol/l blood flow has
proven to be safe.
Conclusions
The study by Schwarzer et al. shows that postfilter iCa
monitoring of regional anticoagulation with citrate may
be unreliable, because the measurement cannot be
validated in the low iCa range. As a result, anticoagula-
tion of the extracorporeal circuit may be suboptimal.
Until reference methods for low iCa in whole blood con-
taining citrate are available, clinicians have good reasons
to mistrust postfilter iCa results, especially in the case of
otherwise unexplained early filter clotting. In these situa-
tions, citrate flow can be safely increased up to 4 mmol/l
blood flow, or higher under close monitoring of signs of
citrate accumulation and acid–base balance.
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